AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36575425
Drug: Inhaled carbon
RxNorm normalized name: carbon dioxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled carbon dioxide (CO)
Trial: 36575505
Drug: Pegloticase +
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegloticase + oral methotrexate (15 mg/week) administered 4 weeks before and during pegloticase treatment (biweekly 8 mg infusion, ≤ 52 weeks)
Trial: 36575513
Drug: Pyrotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib (400 mg once daily) plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Trial: 36575513
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Trial: 36576091
Drug: Latanoprost (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (other formulations)
Trial: 36576173
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus axitinib (avelumab 10 mg/kg every 2 weeks plus axitinib 5 mg twice daily)
Trial: 36576191
Drug: Problem-Solving Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-Solving Therapy for Adherence and Depression (PST-AD) - 6 sessions
Trial: 36576323
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (optimization of drug therapy)
Trial: 36576342
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ≥17.2 g BZ mass and presence of BZ channels
Trial: 36576547
Drug: Low-contrast-dose group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-contrast-dose group (n = 43)
Trial: 36576547
Drug: Standard-contrast-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-contrast-dose group (n = 47)
Trial: 36576860
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment for heavy menstrual bleeding
Trial: 36577165
Drug: Sotorasib (first-in-class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotorasib (first-in-class KRAS inhibitor)
Trial: 36577165
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm treatment (inferior to the best standard of care)
Trial: 36578002
Drug: Intervention (SHHC-2.0):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (SHHC-2.0): Twice-weekly experiential classes focused on exercise, nutrition, and civic engagement.
Trial: 36578040
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg rivaroxaban
Trial: 36578069
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous phage (mixture of four anti-pseudomonal phages)
Trial: 36578194
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg intravenously at weeks 0, 2, and 6 (induction therapy)
Trial: 36578194
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg every 8 weeks during maintenance therapy
Trial: 36578450
Drug: Occupational therapy-led
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy-led fall prevention intervention
Trial: 36578832
Drug: 90-mg ticagrelor
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-mg ticagrelor
Trial: 36578916
Drug: Oral Ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ferrous Sulphate (FS) 200 mg three times a day for 12 weeks
Trial: 36579179
Drug: Swiss low
RxNorm normalized name: Swiss Kriss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swiss low back acupuncture (SLBA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Trial: 36579179
Drug: Standard acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard acupuncture (SA) - 9-week therapy, 15 sessions total (weeks 1-6: two sessions/week, weeks 7-9: one session/week)
Trial: 36579349
Drug: Compound 7460-0250
RxNorm normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound 7460-0250
Trial: 36579443
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of intramuscular nandrolone decanoate every 15 days for 2 years
Trial: 36579494
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin for 3 days
Trial: 36579617
Drug: Ambrisentan low
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan low dose
Trial: 36579617
Drug: Ambrisentan high
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan high dose
Trial: 37332660
Drug: Ambrisentan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (both doses)
Trial: 36579743
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (days 9-28)
Trial: 36580029
Drug: Sucrosomial® iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrosomial® iron (60 mg/day for one month)
Trial: 36580650
Drug: anaprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anaprazole 20 mg once daily for 4 weeks
Trial: 36580650
Drug: rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 10 mg + anaprazole placebo
Trial: 36581186
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice daily for 14 days
Trial: 36581413
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant (CI) and hearing aid (HA) in a bimodal solution (CI+HA)
Trial: 36581874
Drug: Preoperative carbohydrates
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative carbohydrates (CHO) supplement, 50 g carbohydrates orally the evening before surgery (20:00-24:00)
Trial: 36581878
Drug: Efavirenz 50
RxNorm normalized name: efavirenz 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 50 mg
Trial: 36581878
Drug: Efavirenz 200
RxNorm normalized name: efavirenz 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 200 mg
Trial: 36581893
Drug: Metformin (n=194)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (n=194)
Trial: 36581902
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) associated with pain neuroscience education (PNE) and clinical hypnosis (CH)
Trial: 36581902
Drug: PNE, CH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNE, CH, and sham therapy
Trial: 36582243
Drug: Cavrotolimod (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavrotolimod (5, 10, 12.5, and 18.8 µg/kg)
Trial: 36582297
Drug: Nintendo Switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintendo Switch RingFit Adventure (RFA) exergame-based exercise, details on dosage and duration not available.
Trial: 36582423
Drug: Photon beam
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon beam therapy (SCRT with photons)
Trial: 36582742
Drug: NLRP3 variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLRP3 variant G-allele carriers
Trial: 36583171
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg or 300 mg once daily continuously and anlotinib 10 mg (12 mg before protocol amendment) once daily on days 1-14 of each 21-day cycle until disease progression or intolerable toxicity.
Trial: 36583350
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of activated complement
Trial: 36583355
Drug: Finerenone 10
RxNorm normalized name: finerenone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 10 mg once daily for 90 days
Trial: 36583355
Drug: Finerenone 15
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Finerenone 15 mg once daily for 90 days
Trial: 36583355
Drug: Finerenone 20
RxNorm normalized name: finerenone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 20 mg once daily for 90 days
Trial: 36584053
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with ropivacaine 0.75%, 0.35 ml.kg-1
Trial: 36584248
Drug: α-Lipoic Acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-Lipoic Acid (ALA) 100 mg/d
Trial: 36584579
Drug: Nerve-growth-factor injection
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve-growth-factor injection
Trial: 36584711
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning model using early treatment data from STAR*D (baseline and first follow up) to predict remission rates at treatment step 1.
Trial: 36584711
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 2.
Trial: 36584711
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning model using early treatment data from STAR*D to predict remission rates at treatment step 3.
Trial: 36584835
Drug: Discontinued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued treatment early
Trial: 36585127
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg/mL weekly subcutaneous injections
Trial: 36585130
Drug: Enalapril (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (starting at 2.5 mg two times per day, titrating up to a maximum dose of 10 mg two times per day)
Trial: 36585130
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (high-dose anthracycline-based chemotherapy)
Trial: 36585137
Drug: SARS-CoV-2 vaccine
RxNorm normalized name: SARS-CoV-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccine
Trial: 36585139
Drug: Daily synbiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily synbiotic intervention (combining human milk oligosaccharide and probiotic)
Trial: 36585147
Drug: IYCF intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IYCF intervention (behaviour change modules and small-quantity lipid-based nutrient supplements from 6 to 12 months of age)
Trial: 36585408
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.1 mg/day) plus oral micronized progesterone (200 mg/day as 100 mg twice daily)
Trial: 36585491
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (ET) and Placebo (PLC)
Trial: 36585608
Drug: Withdrawal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal or withholding of life-sustaining therapies
Trial: 36585933
Drug: Internet-based exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based exposure therapy for fibromyalgia (10 weeks)
Trial: 36586351
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate treatment (DMF)
Trial: 36586514
Drug: 30-mg oral
RxNorm normalized name: dacomitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg oral melatonin
Trial: 36586583
Drug: 0.5%, 0.75%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5%, 0.75%, or 1.5% ruxolitinib cream applied twice daily for 28 days
Trial: 36587890
Drug: Subcutaneous C.E.R.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous C.E.R.A. administration every 4 weeks
Trial: 36588113
Drug: PBM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM treatment (590, 660 and 850 nm) 3 times per week over 3-4 weeks (9 treatments per series)
Trial: 36588113
Drug: PBM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM treatment
Trial: 36588113
Drug: PBM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM treatment and sham treatment
Trial: 36588137
Drug: Risankizumab 300
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab 300 mg
Trial: 36588741
Drug: Ganshuang granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganshuang granule combined with tenofovir; dosage and duration not available
Trial: 36590787
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg over 40 min)
Trial: 36590789
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg) once daily for 10 days
Trial: 36591610
Drug: Optimised treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised treatments
Trial: 36591610
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy containing metronidazole, tetracycline and bismuth
Trial: 36591610
Drug: Triple amoxicillin-levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple amoxicillin-levofloxacin therapy
Trial: 36591610
Drug: Overall treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatments
Trial: 36591636
Drug: Videoconferencing acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconferencing acceptance and commitment therapy (ACT)
Trial: 36592299
Drug: High-dose cephalexin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cephalexin (1000 mg)
Trial: 36592299
Drug: Standard-dose cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cephalexin (500 mg)
Trial: 36592505
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid 6-monthly (≤6 infusions, n=170)
Trial: 36592505
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid 6-monthly (≥7 infusions, n=555)
Trial: 36592507
Drug: Ipilimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (1 mg/kg every 6 weeks for a maximum of two infusions), Nivolumab (6 mg/kg every four weeks), Tocilizumab (8 mg/kg every four weeks), and SBRT (15 Gy on day one of the first cycle)
Trial: 36592878
Drug: Zalunfiban dose
RxNorm normalized name: Zalunfiban
DrugBank: Zalunfiban (DB18766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalunfiban dose 1 (0.110 mg/kg)
Trial: 36592878
Drug: Zalunfiban dose
RxNorm normalized name: Zalunfiban
DrugBank: Zalunfiban (DB18766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalunfiban dose 2 (0.130 mg/kg)
Trial: 36592878
Drug: Zalunfiban (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalunfiban (both doses)
Trial: 36593652
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine (VarV) and inactivated hepatitis A vaccine (HepA) co-administered (Group A)
Trial: 36593652
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group B) - VarV and HepA administered separately
Trial: 36593702
Drug: Weekly umbilical
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly umbilical artery Doppler ultrasound
Trial: 36593702
Drug: Bi-weekly umbilical
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly umbilical artery Doppler ultrasound
Trial: 36593729
Drug: Corticosteroid tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid tapering in patients receiving subcutaneous daratumumab
Trial: 36594077
Drug: 5 mm-bolus
RxNorm normalized name: Peumus boldus leaf
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mm-bolus daily (HR group)
Trial: 36594167
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin in combination with venetoclax and an anti-CD20 antibody
Trial: 36594428
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LPD) (0.6 to 0.8 g/kg/day)
Trial: 36594428
Drug: Usual or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual or unrestricted protein diet (UPD) (≥ 1.0 g/kg/day)
Trial: 36594748
Drug: Laparoscopy-assisted TME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopy-assisted TME (L-TME)
Trial: 36594947
Drug: Remifentanil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (3 to 4 μg/kg); n=575
Trial: 36594947
Drug: Neuromuscular blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium); n=575
Trial: 36594947
Drug: Remifentanil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (3 to 4 μg/kg); n=565 (per-protocol population)
Trial: 36594947
Drug: Neuromuscular blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium); n=565 (per-protocol population)
Trial: 36594987
Drug: Severity score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severity score 2 (no oxygen therapy)
Trial: 36595569
Drug: Atezolizumab with
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab with standard chemotherapy and bevacizumab
Trial: 36595569
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standard chemotherapy and bevacizumab
Trial: 36596439
Drug: Self-administered, multidimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered, multidimensional bladder health scales and function indices (paper and electronic forms)
Trial: 36596609
Drug: Dexamethasone preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone preparations
Trial: 36596632
Drug: Monthly virtual
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly virtual MS symptom education groups (six sessions)
Trial: 36596682
Drug: Appropriate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate empirical antibiotics
Trial: 36596682
Drug: Inappropriate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate empirical antibiotics
Trial: 36596787
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immune checkpoint inhibitor (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin)
Trial: 36596867
Drug: Symptomatic intracranial
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic intracranial hemorrhage (sICH) after anticoagulants
Trial: 36596867
Drug: Intracranial hemorrhage
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracranial hemorrhage (ICH) after anticoagulants
Trial: 36596867
Drug: Systemic hemorrhage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic hemorrhage after anticoagulants
Trial: 36596945
Drug: Oropharyngeal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal therapy with mother's own milk (OPT-MOM)
Trial: 36597076
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ferroquine plus artefenomel 300 mg